Ovarian carcinoma (high-grade serous predominant) · line 3 · Trabectedin + PLD (recurrent ovarian, OVA-301)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-TRABECTEDIN-PLD-OVARIAN |
| ID | IND-OVARIAN-3L-TRABECTEDIN-PLD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-OVARIAN |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 SRC-OVA-301-MONK-2010 |
Notes
ESCAT IIA. UA-access: trabectedin not registered as of 2026-04; PLD здебільшого OOP. Доступ через клінічне дослідження або благодійний імпорт.
Used By
Algorithms
ALGO-OVARIAN-2L- ALGO-OVARIAN-2L